Revance Therapeutics Inc announces the publication of the pooled data from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies (SAKURA 1 and SAKURA 2) evaluating Revance’s long-acting neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI) for the treatment of moderate to severe glabellar (frown) lines.
A particular challenge in clinical trials is recruiting potential participants. According to author Cher Zavala, there is a clear need to improve study recruitment rates — and the best way to do this is to use a multifaceted approach.
Women receiving biological therapies for psoriasis reported lower satisfaction and more side effects compared with men, according to study data published in the Journal of the European Academy of Dermatology and Venereology.
Nearly 55 percent to 70 percent of the doctors, along with dermatologists, have been inclined to the increasing use of digital tools in the U.S. Still, the adaptation of technology tools also comes with financial, staff, and patient number implications, according to Medical Tech Outlook.
Face filters, which became popular thanks to apps like Snapchat, are now leading some people to use them to show plastic surgeons how they want to look. It is part of a growing problem dubbed selfie dysmorphia, according to NBC New York.